Your session is about to expire
← Back to Search
Atezolizumab + Tiragolumab for Non-Small Cell Lung Cancer (SKYSCRAPER-15 Trial)
SKYSCRAPER-15 Trial Summary
"This trial aims to see if adding tiragolumab to atezolizumab is more effective and safe than just using atezolizumab in patients with non-small cell lung cancer
SKYSCRAPER-15 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSKYSCRAPER-15 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SKYSCRAPER-15 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current number of participants being enrolled in this clinical research study?
"To proceed with the research, we need a cohort of 1150 individuals who satisfy the trial's eligibility criteria. Hoffmann-La Roche is overseeing operations at various centers like Seoul National University Bundang Hospital in Seongnam-si and The Oncology Institute of Hope and Innovation; Cerritos located in Illinois and New mexico respectively."
At how many distinct sites is this clinical trial being conducted?
"Among the options for participation in this study are Seoul National University Bundang Hospital located in Seongnam-si, The Oncology Institute of Hope and Innovation-Cerritos situated in Cerritos, and University of New mexico Cancer Center based in Albuquerque. Additionally, there are eleven alternative sites available for enrollment."
Has the FDA officially authorized the combination of Atezolizumab and Tiragolumab for medical use?
"Power's assessment ranks the safety of Atezolizumab + Tiragolumab at 3 out of a possible scale range up to 3 due to its Phase 3 status, which signifies existing evidence backing effectiveness and robust safety data."
Share this study with friends
Copy Link
Messenger